Skip to content
OpenCapital
Get started

Madrigal Pharmaceuticals, Inc. MDGL Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Teradyne, Inc. logo
Teradyne, Inc.TER
$3.65M-88.6%
Paychex logo
PaychexPAYX
$0-100%
Teradyne, Inc. logo
Teradyne, Inc.TER
$148.37M+30.4%
DexCom logo
DexComDXCM
$1.3B—
Popular logo
PopularBPOP
——
Popular logo
PopularBPOP
——

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M—
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M—
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%—
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s available for sale securities debt securities current?
Madrigal Pharmaceuticals, Inc. (MDGL) reported available for sale securities debt securities current of $585.74M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s available for sale securities debt securities current changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s available for sale securities debt securities current decreased by 11.2% year-over-year, from $659.42M to $585.74M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s available for sale securities debt securities current?
Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s available for sale securities debt securities current has grown at a 27.8% compound annual growth rate (CAGR), from $230.15M to $784.87M.